Sunday, September 13, 2026

International Business

3 articles

US Cannabis Firm Vireo Faces $5M+ Per-State Compliance Burden in $300M+ Scotts Miracle-Gro Deal

US Cannabis Firm Vireo Faces $5M+ Per-State Compliance Burden in $300M+ Scotts Miracle-Gro Deal

Vireo Growth confronts regulatory fragmentation across 38 US state markets following its acquisition of Scotts Miracle-Gro's Hawthorne cannabis division and Eaze delivery platform. Federal prohibition forces $3-5 million annual compliance spending per state license, while Section 280E tax restrictions create 70-80% effective tax rates. The regulatory patchwork contrasts sharply with unified frameworks in Canada, Germany, and Uruguay's legal cannabis markets.

ViaNews Editorial Team
China Targets $2.8B Monthly Casino Pipeline as Macao Faces Visitor Restrictions

China Targets $2.8B Monthly Casino Pipeline as Macao Faces Visitor Restrictions

Beijing is moving to restrict mainland Chinese access to Macao's casinos, threatening $2.8 billion in monthly capital flows. New visitor permit rules would require business justifications for entry, while payment restrictions could block WeChat Pay and Alipay transactions that fund 40% of casino profits.

ViaNews Editorial Team
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com